These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 34157302)

  • 41. Induction of immune tolerance in asthmatic mice by vaccination with DNA encoding an allergen-cytotoxic T lymphocyte-associated antigen 4 combination.
    Zhang F; Huang G; Hu B; Song Y; Shi Y
    Clin Vaccine Immunol; 2011 May; 18(5):807-14. PubMed ID: 21346053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer.
    Matoba T; Imai M; Ohkura N; Kawakita D; Ijichi K; Toyama T; Morita A; Murakami S; Sakaguchi S; Yamazaki S
    Int J Cancer; 2019 Jun; 144(11):2811-2822. PubMed ID: 30485427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4: A comprehensive protein-protein modelling study.
    Ganesan A; Moon TC; Barakat KH
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2764-2778. PubMed ID: 30251665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
    Linsley PS; Greene JL; Tan P; Bradshaw J; Ledbetter JA; Anasetti C; Damle NK
    J Exp Med; 1992 Dec; 176(6):1595-604. PubMed ID: 1334116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A transendocytosis perspective on the CD28/CTLA-4 pathway.
    Soskic B; Qureshi OS; Hou T; Sansom DM
    Adv Immunol; 2014; 124():95-136. PubMed ID: 25175774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.
    Kong KF; Fu G; Zhang Y; Yokosuka T; Casas J; Canonigo-Balancio AJ; Becart S; Kim G; Yates JR; Kronenberg M; Saito T; Gascoigne NR; Altman A
    Nat Immunol; 2014 May; 15(5):465-72. PubMed ID: 24705298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.
    Liu Y; Zheng P
    Trends Pharmacol Sci; 2020 Jan; 41(1):4-12. PubMed ID: 31836191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis.
    Soskic B; Jeffery LE; Kennedy A; Gardner DH; Hou TZ; Halliday N; Williams C; Janman D; Rowshanravan B; Hirschfield GM; Sansom DM
    Front Immunol; 2020; 11():577655. PubMed ID: 33488578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Confusing signals: recent progress in CTLA-4 biology.
    Walker LS; Sansom DM
    Trends Immunol; 2015 Feb; 36(2):63-70. PubMed ID: 25582039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy.
    Ou W; Thapa RK; Jiang L; Soe ZC; Gautam M; Chang JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
    J Control Release; 2018 Jul; 281():84-96. PubMed ID: 29777794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerogenic dendritic cells suppress murine corneal allograft rejection by modulating CD28/CTLA-4 expression on regulatory T cells.
    Yan F; Cai L; Hui Y; Chen S; Meng H; Huang Z
    Cell Biol Int; 2014 Jul; 38(7):835-48. PubMed ID: 24604878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria.
    Barnes MJ; Griseri T; Johnson AM; Young W; Powrie F; Izcue A
    Mucosal Immunol; 2013 Mar; 6(2):324-34. PubMed ID: 22910217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.
    Maj T; Wang W; Crespo J; Zhang H; Wang W; Wei S; Zhao L; Vatan L; Shao I; Szeliga W; Lyssiotis C; Liu JR; Kryczek I; Zou W
    Nat Immunol; 2017 Dec; 18(12):1332-1341. PubMed ID: 29083399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
    Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nonclassical CD4+CD49b+ Regulatory T Cells as a Better Alternative to Conventional CD4+CD25+ T Cells To Dampen Arthritis Severity.
    Vicente R; Quentin J; Mausset-Bonnefont AL; Chuchana P; Martire D; Cren M; Jorgensen C; Louis-Plence P
    J Immunol; 2016 Jan; 196(1):298-309. PubMed ID: 26590312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells.
    Cong L; Wang SF; Zhao ZL; Yang RY
    Transplantation; 2016 Apr; 100(4):763-71. PubMed ID: 26569069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.